Le Lézard
Subjects: Product/Service, Trade Show

Ora Unveils Groundbreaking Ophthalmic Research Technologies at ARVO 2022


Ora serves industry innovators by de-risking and accelerating development programs to demonstrate the efficacy of novel therapies through data-driven study design, global execution, and validated technologies that directly improve the likelihood of study success. To date, they have helped their clients achieve over 50 product approvals through a people-first, systems-oriented model of operational excellence. From advancements in retinal and dry eye research, to revolutionary endpoint technology, the people that deliver Ora's global services will be on full display at this year's Association for Research in Ophthalmology Conference (ARVO) in Denver, CO, May 1st ? 4th.

"We love ARVO," said Stuart B. Abelson, President, CEO and Chairman of Ora, "It has been an essential showcase for Ora's research and development efforts since 1972 when my father, Ora's founder, Dr. Mark Abelson, first presented research. Now, 50 years later, Ora continues to be inspired by the ARVO experience as the crossroads of science and creativity in ophthalmology. We are energized by serving and collaborating with the most forward-thinking companies in ophthalmology and look forward to sharing the results of our work. Please come visit us and share your exciting project ? let's explore how to make that vision a reality."

SIG Event

Ora's latest innovations in proactive AMD endpoints signify a paradigm shift in how the disease will be treated as well as measuring improvement in patients' quality of life. Ora is proud to have Gus De Moraes, MD, PhD, MPH, and Chief Medical Officer at Ora, lead a SIG discussing these solutions for vision loss caused by AMD. This panel will feature the Director of Ora Retina Institute John Rodriguez PhD, Karl Csaky MD, PhD, and Giovanni Straurenghi MD, PhD.

"Functional endpoints for early-to-intermediate age-related macular degeneration (AMD): current status and future directions" by Dr. Gus De Moraes

Note that Dr. De Moraes will also be hosting a session "Structure-Function Relationship" at ARVO

"I am passionate about identifying and resolving ocular diseases in their earliest stages, such as age-related macular degeneration, before they begin to seriously impair functional vision and quality of life. I am honored to support the development of these highly proactive endpoint programs aimed to help those who unnecessarily suffer from AMD." ? Gus De Moraes, MD, PhD, MPH

Scientific Presentations

Ora Technologies Enable New Endpoints and Power Decentralized Trials

The Ora EyeCupTM Phone is a validated remote image capture system that is currently being used in trials around the world. Ora's imaging and AI analysis capabilities enhance trial design and execution in many ways. Come learn how to maximize your chances of success with accurate real-time data that reduces variability, improves compliance, and accelerates study timelines. Ethan Bensinger PhD, Ora's Visual Psychophysics Specialist, and Igor Sinyak, Ora's Head of Technology, look forward to showcasing this dynamic technology.

"Tear film stability measured with the Ocular Protection Index (OPI) acquired with Ora EyeCupTM Phone" by Ethan Bensinger

"Reliability of Redness Imaging with the Ora EyeCupTM Phone" by Igor Sinyak

Novel Retina Research

For years, the Ora team has studied early AMD progression in pursuit of more sensitive endpoints to develop therapies that combat the deterioration of vision before it encroaches upon functional acuity. With the power of the latest technology, the team is proud to share the latest developments in endpoint design and validation.

"Variable contrast flicker in patients with non-advanced age-related macular degeneration: results from the 3rd year follow-up" John Rodriguez will be presenting on behalf of Doina Gherghel

"A Novel Test of Low Contrast Reading in Non-Advanced Age-Related Macular Degeneration: A Potential Functional Endpoint for Clinical Trials" by Matt Dusharm, displayed by Ethan Bensinger

In collaboration with their clients, Ora has facilitated an array of novel therapeutic approaches to ocular diseases such as a designed molecule treatment for Dry Eye, an investigational gene therapy solution to AMD, and a new topical ocular allergy medication. Learn more about how Ora is actively shifting the paradigm of clinical development in the industry:

"A multi-center phase 3 evaluation of Bilastine 0.6% preservative-free eye drops for the treatment of allergic conjunctivitis" by Paul Gomes

"Safety and efficacy of ophthalmic mitochondrial reactive oxygen species scavenger Visomitin for the treatment of dry eye disease: findings of VISTA-1 and VISTA-2 studies" by George Ousler

Continued

"Dry Eye Symptom Relief and Quality of Life Improvements Associated with Administration of AR-15512" by David Wirta

"Melanocortin agonist PL9643 significantly improves ocular signs and symptoms of moderate to severe dry eye disease (DED), including tear film break up time (TFBUT)" by David Evans

"CCN5 gene delivery is beneficial in a sodium-iodate challenge model of dry age-related macular degeneration" by Zsolt Ablonczy

Ora at ARVO 2022 (Booth #2115)

Come experience how over forty years of ophthalmic innovation is shaping the future of clinical development. With a global research community designed to optimize site preparedness, study execution, and global data, Ora's systems and programs provide unparalleled support and expanded feasibility. Explore interactive displays, Ora EyeCupTM demonstrations, and presentations by subject matter experts to discover how Ora sets the standard for global product development.

About Ora, Inc.

Ora is the world's leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Australia, and Asia. For over 40 years, we have proudly helped our clients earn more than 55 product approvals and create vision beyond what they see. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and operations management to maximize the value of new product initiatives. Think ophthalmology, think Ora. For more information, please visit www.oraclinical.com, like us on Facebook, and follow us on LinkedIn.



News published on and distributed by: